Merck Adds To Phase III Pipeline With Lundbeck Sleep-Aid Gaboxadol
Merck's $270 mil. licensing deal for Lundbeck's Phase III sleep disorder agent gaboxadol could give Merck a fifth new product approval around the time that Zocor comes off patent
Merck's $270 mil. licensing deal for Lundbeck's Phase III sleep disorder agent gaboxadol could give Merck a fifth new product approval around the time that Zocor comes off patent